HSBC Holdings
JUNO

HSBC Holdings’s Juno Therapeutics, Inc. JUNO Stock Holding History

HSBC Holdings’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,703
Closed -$211K – 2492
2017
Q3 		$211K Sell
4,703
-2,640
-36% -$90K ﹤0.01% 2137
2017
Q2 		$219K Sell
7,343
-10,022
-58% -$247K ﹤0.01% 2012
2017
Q1 		$385K Sell
17,365
-3,540
-17% -$75.9K ﹤0.01% 1698
2016
Q4 		$394K Buy
20,905
+13,328
+176% +$326K ﹤0.01% 2023
2016
Q3 		$227K Buy
7,577
+1,509
+25% +$46.9K ﹤0.01% 1874
2016
Q2 		$233K Sell
6,068
-81,021
-93% -$3.36M ﹤0.01% 1868
2016
Q1 		$3.32M Sell
87,089
-1,741
-2% -$60.7K 0.01% 1020
2015
Q4 		$3.9M Sell
88,830
-2,240
-2% -$111K 0.01% 1017
2015
Q3 		$3.71M Buy
91,070
+2,666
+3% +$117K 0.01% 900
2015
Q2 		$4.71M Buy
+88,404
New +$4.69M 0.01% 844

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

HSBC Holdings's JUNO Position: Q4 2017 in Review

HSBC Holdings sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 4,703 shares — an estimated $211K sold.

HSBC Holdings first reported a position in JUNO in Q2 2015 and held it in 10 quarters. The position peaked at $4.71M in Q2 2015. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • HSBC Holdings reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • HSBC Holdings sold 4,703 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $211K.
  • HSBC Holdings first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 10 quarters.
  • HSBC Holdings's Juno Therapeutics, Inc. position peaked at $4.71M in Q2 2015.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on HSBC Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.